- Latest Innovations, Drivers, Restraints, Challenges and Key Events in the industry by 2024

Comments

Transcription

- Latest Innovations, Drivers, Restraints, Challenges and Key Events in the industry by 2024
Recurrent Glioblastoma Multiforme (GBM) Treatment Market :
Global Industry Analysis and Forecast 2016 - 2022
Persistence Market Research
Recurrent Glioblastoma Multiforme (GBM)
Treatment Market : Global Industry Analysis
and Forecast 2016 - 2022
Persistence Market Research
1
Recurrent Glioblastoma Multiforme (GBM) Treatment Market :
Global Industry Analysis and Forecast 2016 - 2022
Persistence Market Research Released New Market Report on “Recurrent Glioblastoma
Multiforme (GBM) Treatment Market : Global Industry Analysis and Forecast 2016 - 2022”.
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in
humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma
and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or
the brain, the latter being more common. Gliomas are the most common type of brain tumor and
can be either supratentorial or infratentorial. Seizure, nausea, headache, hemiparesis and
memory loss are some of the common symptoms observed in the patients suffering from GBM.
GBM is most commonly found in male with the age of 65 years and above.
Alcohol consumption and malaria are the possible risk factors for the development of GBM. In
addition, neurofibromatosis, tuberous sclerosis, von-hippel-lindau disease, Li-fraumeni
syndrome and turcot syndrome are some of the genetic disorders that are associated with
increasing incidences of gliomas. Glioblastoma multiforme is a World Health Organization
Grade IV tumor that represents 15 to 20% of all primary intracranial tumors.
Interested in report: Please follow the below links to meet your requirements;
Request for the Report Brochure: http://www.persistencemarketresearch.com/samples/10112
Increasing habits of alcohol consumption, changing lifestyle and increasing incidence of seizure
are some of the drivers for the growth of GBM market. GBM is generally treated by first
surgically removing the tumor then treating with chemotherapy and radiation. While this
treatment plan is the currently accepted standard of care, it does not effectively prevent tumor
recurrence, which ultimately causes death in GBM patients. This factor is expected to be the
prime restraint for the growth of recurrent glioblastoma multiforme market.
Persistence Market Research
2
Recurrent Glioblastoma Multiforme (GBM) Treatment Market :
Global Industry Analysis and Forecast 2016 - 2022
Recurrent Glioblastoma Multiforme (GBM) market is segmented on the basis of treatment, end
user and geography.
Request TOC (table of content), Figures and Tables of the Report:
http://www.persistencemarketresearch.com/toc/10112
Based on treatment, GBM market can be segmented as follows:
•
Oral Medications
•
Temozolomide
•
Radiosensitizers
•
Nitrosoureas Drugs
•
Radiation therapy
•
Chemotherapy
Based on end user, GBM market can be segmented as follows:
•
Hospitals
•
Clinics
•
Ambulatory surgical centers
Primary treatment involves surgery to achieve tumor debulking, followed by a multimodal
regimen of radiotherapy and chemotherapy. Chemotherapy can be added to radiotherapy for
patients with unfavorable low-grade glioma to improve progression free survival. The most
frequently used chemotherapy regimens are a combination of procarbazine, lomustine and
vincristine, or single-agent treatment with carmustine or lomustine. Temozolomide is
Persistence Market Research
3
Recurrent Glioblastoma Multiforme (GBM) Treatment Market :
Global Industry Analysis and Forecast 2016 - 2022
recommended by NICE as an option for the treatment of newly diagnosed GBM. Concomitant
and adjuvant chemotherapy with temozolomide given during and after radiotherapy improves
survival. This drug used along with chemotherapy or radiotherapy has led to the growth of GBM
treatment market to a great extent.
Region wise, the global recurrent glioblastoma multiforme (GBM) market is classified into
regions namely, North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
North America and Europe dominates the global GBM market owing to rising awareness,
population aging, changing lifestyle and increasing healthcare awareness accentuates the
growth of GBM market in these regions. In addition, Asia-Pacific region is expected to be an
emerging market due to increasing demand for better healthcare facilities.
Some of the companies competing in recurrent glioblastoma multiforme (GBM) treatment
market are Astrazeneca, F. Hoffman-La Roche, Ltd., GlaxoSmithKline plc., Merck & Co., Inc.,
Pfizer, Inc., AngioChem, Inc. Vascular Biogeneics and others.
The report covers exhaustive analysis on:
•
Recurrent Glioblastoma Multiforme (GBM) Treatment Market Segments
•
Recurrent Glioblastoma Multiforme (GBM) Treatment Market Dynamics
•
Historical Actual Market Size, 2013 - 2015
•
Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size & Forecast 2016 to
2022
•
Recurrent Glioblastoma Multiforme (GBM) Treatment Current Trends/Issues/Challenges
•
Competition & Companies involved
•
Recurrent Glioblastoma Multiforme (GBM) Treatment Drivers and Restraints
Persistence Market Research
4
Recurrent Glioblastoma Multiforme (GBM) Treatment Market :
Global Industry Analysis and Forecast 2016 - 2022
Regional analysis includes
•
North America
•
Latin America
•
Europe
•
Asia Pacific
•
Middle East & Africa
For more info: http://www.persistencemarketresearch.com/contact-us.asp
Report Highlights:
•
Shifting Industry dynamics
•
In-depth market segmentation
•
Historical, current and projected industry size Recent industry trends
•
Key Competition landscape
•
Strategies of key players and product offerings
•
Potential and niche segments/regions exhibiting promising growth
•
A neutral perspective towards market performance
Follow us on: https://www.linkedin.com/company/persistence-market-research-&-consulting
Persistence Market Research
5
Recurrent Glioblastoma Multiforme (GBM) Treatment Market :
Global Industry Analysis and Forecast 2016 - 2022
About Us:
Persistence Market Research (PMR) is a full-service market intelligence firm specializing in
syndicated research, custom research, and consulting services. PMR boasts market research
expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and
Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping
and Transportation industries. The company draws from its multi-disciplinary capabilities and
high-pedigree team of analysts to share data that precisely corresponds to clients’ business
needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions.
From ready-to-purchase market research reports to customized research solutions, PMR’s
engagement models are highly flexible without compromising on its deep-seated research
values.
Contact Us:
Persistence Market Research
305 Broadway, 7th Floor,
New York City, NY 10007,
United States.
Phone: +1-646-568-7751
USA/Canada Toll Free Number: +1-800-961-0353
E-mail: [email protected]
Web : http://www.persistencemarketresearch.com
Persistence Market Research
6

Similar documents

Latest Report: Glioblastoma Treatment Market Will Expand Fivefold to $3.3 Billion at a CAGR of 17.4% by 2024

Latest Report: Glioblastoma Treatment Market Will Expand Fivefold to $3.3 Billion at a CAGR of 17.4% by 2024 The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, representing a rapid Compound Annual Growth Rate (CAGR) of 17.4% according to a leading research and consulting firm. Of the 7MM, Japan will see the most impressive relative growth, with sales expanding from $47 million in 2014 to $268 million in 2024, representing a CAGR of 19.7%.

More information